The size of the global bladder cancer therapeutics market is expected to reach USD 321.00 million by 2026 from USD 252.11 million in 2021, growing at a CAGR of 4.95% during the forecast period.
Bladder cancer is the uncontrolled growth of abnormal cells in the urinary bladder lining with the epithelial cells. These cells even spread through the lining into the muscular wall of the bladder. Several therapies have currently evolved to treat bladder cancer; thus, it builds a higher demand for the bladder cancer therapeutics market. The cancerous tissue is known as tumors and can spread to other nearby cells and tissues if not treated at the earliest stage. Urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others are the treatment for bladder cancer. According to the American cancer society, 81,400 new cancer cases were registered in 2020 out. Of them, it was estimated that 62,100 were men and 19,300 were women cancer patients. In 2019, the center for drug research and development in CANADA announced USD 1.2 million investment in Sitka biopharma. The development activities for clinical trials named STK-01 are used to treat bladder cancer nanotechnology.
MARKET DRIVERS:
The increasing incidence of tumors, innovations of drugs for treatment, and technological advances are primarily accelerating the global bladder cancer therapeutics market growth.
As this cancer is more common in adults over 50 years, the increase in the geriatric population also contributes to the market's growth. Furthermore, government initiatives increased awareness of bladder cancer, and available treatments and progressive health services associated with increased spending on health care also boost the global Bladder Cancer Therapeutics Market. Since cancer is an asymptomatic disease in the initial stage, it requires an accurate diagnosis at an early stage.
Technological advancements, new treatments, advanced healthcare services, and increasing knowledge about bladder cancer therapies among the people, the launch of new novel drugs, and the acceptance of effective diagnostic tools, and also the rise in healthcare expenditure are the factors that drive the global bladder cancer therapeutics market growth.
Launch of new products, rise in the investments in research and development, and the manufacturing demand increases pose differentiable growth opportunities in the global bladder cancer therapeutics market.
MARKET RESTRAINTS:
Factors such as less availability of various treatment options, an increase in healthcare services, and increasing knowledge about all kinds of cancers are the facts that are hindering the global bladder cancer therapeutics market growth. High costs that are associated with the devices may hamper the growth. In addition, strict regulatory policies, poorly developed healthcare infrastructure, and limited adoption of advanced cancer therapies hinder the growth.
The challenges facing the bladder cancer therapeutics market are that people in rural areas are less aware of the treatment procedures available and less availability for skilled persons in diagnostic centers.
Impact of COVID-19 on the global bladder cancer therapeutics market:
The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) has affected many individuals and healthcare systems. The primary concern is associated with the difficulty in engaging with healthcare systems. Bladder cancer majorly occurs in the elderly population. The global economy and the market had been adversely affected; the market structure has been completely changed. Countries are in a global run to expand and produce a vaccine for the SARS-COV-2. Government bodies are increasing funding for vaccine development. Nationwide lockdown had been implemented due to a surge in the covid-19 cases. The concerning activities on bladder cancer therapeutics had stopped and been postponed.
The market is expecting significant market growth despite the negative impact on the initial period of 2020. The number of new bladder cancer cases has been registered in the recent period through which market expansion can be possible. In addition, different cancer therapies such as immunotherapies in the cancer treatment recharged among the people. It recently developed treatment modalities which are conventional therapeutics options in bladder cancer management. However, the market is anticipated to witness a healthy growth rate during the forecast period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Analysed |
By Type, Treatment, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Companies Analysed |
Sanofi S.A., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., And Celgene Corporation |
This research report on the global bladder cancer therapeutics market has been segmented and sub-segmented based on type, treatment, and region.
Bladder Cancer Therapeutics Market - By Type:
Based on the type, the transitional cell bladder segment holds the market share in the market due to improving healthcare infrastructures in developed and developing countries.
Bladder Cancer Therapeutics Market - By Treatment:
Based on the treatment type, the Chemotherapy segment holds the highest market share due to the many chemotherapy drugs.
Bladder Cancer Therapeutics Market - By Region:
Geographically, North America commanded a significant share of 41.0% of the global bladder cancer therapeutics market in 2019. In contrast, Asia-Pacific is expected to grow at the highest CAGR of 5.68% from 2020 to 2025.
North America leads the world market for bladder cancer. Most of the region is attributed to increased bladder cancer incidence, innovative healthcare solutions, advanced healthcare infrastructure, and growing concern about bladder problems. Europe represents the second largest market share. However, the global bladder cancer market in Asia-Pacific is expected to experience substantial growth. This increase is mainly due to the growing awareness of bladder diseases and innovative diagnostic and treatment options. The leading market players believe that Asian countries are lucrative markets for bladder cancer and make significant investments, leading to market growth.
KEY MARKET PLAYERS:
Companies leading the Global Bladder Cancer Therapeutics Market profiled in the report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland) and Celgene Corporation (U.S.)
RECENT MARKET DEVELOPMENTS:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Non Muscle Invasive/Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Adenocarcinoma of the Bladder
5.1.6 Rare Bladder Cancers
5.2 By Treatment
5.2.1 Surgery
5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)
5.2.1.2 Cystectomy
5.2.1.3 Urinary Diversion
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Radiation Therapy
5.2.5 Intravesical Therapy
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Sanofi S.A. (France)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 GlaxoSmithKline plc (U.K.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca plc (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Celgene Corporation (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
